The Misha knee system is designed to be implanted in an outpatient procedure, Moximed said Aug. 16. It is intended as an alternative to total knee replacement for patients with mild to moderate osteoarthritis.
The series C equity and debt financing round was led by Advent Life Sciences, Moximed said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.